Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0002736 (
amyotrophic lateral sclerosis
)
19,048
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
The presence of oxidative damage and increased iron deposition in CNS tissues of
ALS
patients prompted the authors to examine the prevalence of two common
HFE
gene mutations linked to iron accumulation and consequent oxidative stress. The prevalence of the C282Y and H63D mutations was nearly identical in 51
ALS
patients and 47 normal control subjects. The presence of either mutation did not significantly affect the age at onset or rate of progression in
ALS
.
...
PMID:HFE mutations are not strongly associated with sporadic ALS. 1513 93
Iron misregulation promotes oxidative stress and abnormally high iron levels have been found in the spinal cords of patients with
ALS
. The authors investigated whether
HFE
gene polymorphisms, linked to hemochromatosis, are associated with
ALS
using two independent populations of patients with sporadic
ALS
and controls (totaling 379 patients and 400 controls). They found that the H63D polymorphism is overrepresented in individuals with sporadic
ALS
(odds ratio 1.85, CI: 1.35 to 2.54).
...
PMID:Association of the H63D polymorphism in the hemochromatosis gene with sporadic ALS. 1618 39
An abnormal accumulation and distribution of brain iron are common to different neurodegenerative disorders, including Parkinson's disease (PD), and alteration of genes involved in iron metabolism cause neurodegeneration with brain iron accumulation.
HFE
participates in the regulation of iron metabolism, its mutations are primary cause of hereditary hemochromatosis and appear to be more frequent in neurodegenerative disorders such as Alzheimer's disease and
amyotrophic lateral sclerosis
. However, conflicting results were obtained in previous studies aimed to verify if nucleotide variations in
HFE
gene act as risk modifiers for PD. We used denaturing HPLC for scanning DNA sequence variations in exon 2 and 4 of
HFE
gene in a cohort of 475 Italian PD patients. We identified the most common H63D, C282Y and S65C, and also other 4 rare mutation types (R66H, R224W, E277K, and T281M). The allele frequency of H63D and C282Y was not statistically different from that of 2 control groups with similar mean age or of a large cohort of the same geographical area. In addition we could not find statistical differences in the clinical phenotypes of patients carrying at least one mutated
HFE
allele from those with the normal allele. We conclude that in the Italian population, the most common
HFE
mutations, H63D and C282Y are not associated with the individual risk to develop PD, nor have specific influence on the clinical features of the disease.
...
PMID:HFE gene mutations in a population of Italian Parkinson's disease patients. 1832 20
Iron is essential in the brain, yet too much iron can be toxic. Tight regulation of iron in the brain may involve intrinsic mechanisms that control internal homeostasis independent of systemic iron status. Iron abnormalities occur in various neurological disorders, usually with symptoms or neuropathology associated with movement impairment or behavioral disturbances rather than cognitive impairment or dementia. Consistent with this, polymorphisms in the
HFE
gene, associated with the iron overload disorder hemochromatosis, show stronger associations with the movement disorder
amyotrophic lateral sclerosis
(motor neuron disease) than with cognitive impairment. Such associations may arise because certain brain regions involved in movement or executive control are particularly iron-rich, notably the basal ganglia, and may be highly reliant on iron. Various mechanisms, including iron redistribution causing functional iron deficiency, lysosomal and mitochondrial abnormalities or oxidative damage, could underlie iron-related neuropathogenesis. Clarifying how iron contributes causatively to neurodegeneration may improve treatment options in a range of neurodegenerative disorders. This review considers how modern molecular genetic approaches can be applied to resolve the complex molecular systems and pathways by which brain iron homeostasis is regulated and the molecular changes that occur with iron dyshomeostasis and neuropathogenesis.
...
PMID:Molecular genetic approaches to understanding the roles and regulation of iron in brain health and disease. 2034 52
Iron accumulation in the brain and increased oxidative stress are consistent observations in many neurodegenerative diseases. Thus, we have begun examination into gene mutations or allelic variants that could be associated with loss of iron homeostasis. One of the mechanisms leading to iron overload is a mutation in the
HFE
gene, which is involved in iron metabolism. The 2 most common
HFE
gene variants are C282Y (1.9%) and H63D (8.9%). The C282Y
HFE
variant is more commonly associated with hereditary hemochromatosis, which is an autosomal recessive disorder, characterized by iron overload in a number of systemic organs. The H63D
HFE
variant appears less frequently associated with hemochromatosis, but its role in the neurodegenerative diseases has received more attention. At the cellular level, the
HFE
mutant protein resulting from the H63D
HFE
gene variant is associated with iron dyshomeostasis, increased oxidative stress, glutamate release, tau phosphorylation, and alteration in inflammatory response, each of which is under investigation as a contributing factor to neurodegenerative diseases. Therefore, the
HFE
gene variants are proposed to be genetic modifiers or a risk factor for neurodegenerative diseases by establishing an enabling milieu for pathogenic agents. This review will discuss the current knowledge of the association of the
HFE
gene variants with neurodegenerative diseases:
amyotrophic lateral sclerosis
, Alzheimer's disease, Parkinson's disease, and ischemic stroke. Importantly, the data herein also begin to dispel the long-held view that the brain is protected from iron accumulation associated with the
HFE
mutations.
...
PMID:HFE gene variants affect iron in the brain. 2134 98
A specific polymorphism in the hemochromatosis (
HFE
) gene, H63D, is over-represented in neurodegenerative disorders such as
amyotrophic lateral sclerosis
and Alzheimer disease. Mutations of
HFE
are best known as being associated with cellular iron overload, but the mechanism by which
HFE
H63D might increase the risk of neuron degeneration is unclear. Here, using an inducible expression cell model developed from a human neuronal cell line SH-SY5Y, we reported that the presence of the
HFE
H63D protein activated the unfolded protein response (UPR). This response was followed by a persistent endoplasmic reticulum (ER) stress, as the signals of UPR sensors attenuated and followed by up-regulation of caspase-3 cleavage and activity. Our in vitro findings were recapitulated in a transgenic mouse model carrying Hfe H67D, the mouse equivalent of the human H63D mutation. In this model, UPR activation was detected in the lumbar spinal cord at 6 months then declined at 12 months in association with increased caspase-3 cleavage. Moreover, upon the prolonged ER stress, the number of cells expressing
HFE
H63D in early apoptosis was increased moderately. Cell proliferation was decreased without increased cell death. Additionally, despite increased iron level in cells carrying
HFE
H63D, it appeared that ER stress was not responsive to the change of cellular iron status. Overall, our studies indicate that the
HFE
H63D mutant protein is associated with prolonged ER stress and chronically increased neuronal vulnerability.
...
PMID:Mutant HFE H63D protein is associated with prolonged endoplasmic reticulum stress and increased neuronal vulnerability. 2134 49
Our objective was to investigate whether the C282Y (p.Cys 282 Tyr) and H63D (p. His 63 Asp)
HFE
polymorphisms were associated with sporadic
amyotrophic lateral sclerosis
(SALS) in the French population. We searched for a relation of
HFE
polymorphisms with the clinical characteristics of the disease. The
HFE
polymorphisms were studied in 824 patients with SALS and 583 controls. We compared the frequency of the polymorphisms between SALS and controls groups by univariate and multivariate statistics, taking into account gender, site, age-at-onset and survival. We did not observe significant difference in the frequency of H63D polymorphism between SALS and control group. We observed a significant difference for C282Y between patients and controls with a low frequency of the Y allele in patients (3.2%) compared to our control group (5.9%). Disease duration, distribution of gender, site-of-onset, age-at-onset did not differ between groups taking into account genotypes of each polymorphism. Our results in this large cohort of
ALS
patients indicate that H63D polymorphism is not associated with SALS in the French population. This conclusion does not exclude a weak effect of the
HFE
gene polymorphisms in certain
ALS
populations, or an effect of other rare
HFE
gene variants.
...
PMID:Study of the HFE gene common polymorphisms in French patients with sporadic amyotrophic lateral sclerosis. 2242 14
The H63D polymorphism in
HFE
has frequently been associated with susceptibility to
amyotrophic lateral sclerosis
(
ALS
). Regarding the role of
HFE
in iron homeostasis, iron accumulation is considered an important process in
ALS
. Furthermore, novel therapeutic strategies are being developed targeting this process. Evidence for this genetic association is, however, limited to several small studies. For this reason we studied the H63D polymorphism in a large European cohort including 3962
ALS
patients and 5072 control subjects from 7 countries. After meta-analysis of previous studies and current findings we conclude that the H63D polymorphism in
HFE
is not associated with susceptibility to
ALS
, age at disease onset, or survival.
...
PMID:H63D polymorphism in HFE is not associated with amyotrophic lateral sclerosis. 2306 43
Genetic insights into the pathophysiology of
amyotrophic lateral sclerosis
(
ALS
) are untangling the clinical heterogeneity that may contribute to poor clinical trial outcomes and thus to a lack of effective treatments. Mutations in a large number of genes, including SOD1, C9ORF72, TARDBP, FUS, VAPB, VCP, UBQLN2, ALS2, SETX, OPTN, ANG, and SPG11, are thought to cause
ALS
, whereas others, including ATAXN2, GRN,
HFE
, NEFH, UNC13A, and VEGF, appear to be disease-modifying genes. Epigenetic influences may also play important roles. An improved understanding of
ALS
genetics should lead to better trial designs, insights into common molecular pathways, and better characterization of preclinical models. New genetic sequencing techniques, which use high-throughput methods to assess variants across the genome or exome, may facilitate rational patient stratification for clinical trials and permit more individualized prognostic information and treatment decisions in clinical care. Muscle Nerve 49: 786-803, 2014.
...
PMID:Genetic heterogeneity of amyotrophic lateral sclerosis: implications for clinical practice and research. 2448 89
Iron homeostasis dysregulation has been regarded as an important mechanism in neurodegenerative diseases. The H63D and C282Y polymorphisms in the
HFE
gene may be involved in the development of sporadic
amyotrophic lateral sclerosis
(
ALS
) through the disruption of iron homeostasis. However, studies investigating the relationship between
ALS
and these two polymorphisms have yielded contradictory outcomes. We performed a meta-analysis to assess the roles of the H63D and C282Y polymorphisms of
HFE
in
ALS
susceptibility. PubMed, MEDLINE, EMBASE, and Cochrane Library databases were systematically searched to identify relevant studies. Strict selection criteria and exclusion criteria were applied. Odds ratios (ORs) with 95% confidence intervals (CIs) were used to assess the strength of associations. A fixed- or random-effect model was selected, depending on the results of the heterogeneity test. Fourteen studies were included in the meta-analysis (six studies with 1692 cases and 8359 controls for C282Y; 14 studies with 5849 cases and 13,710 controls for H63D). For the C282Y polymorphism, significant associations were observed in the allele model (Y vs C: OR=0.76, 95%CI=0.62-0.92, P=0.005) and the dominant model (YY+CY vs CC: OR=0.75, 95%CI=0.61-0.92, P=0.006). No associations were found for any genetic model for the H63D polymorphism. The C282Y polymorphism in
HFE
could be a potential protective factor for
ALS
in Caucasians. However, the H63D polymorphism does not appear to be associated with
ALS
.
...
PMID:Mutations in the HFE gene and sporadic amyotrophic lateral sclerosis risk: a meta-analysis of observational studies. 2460 26
1
2
Next >>